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AbstrACt
Introduction Systematic reviews of high-quality 
randomised controlled trials are necessary to identify 
effective interventions to impact burn wound infection 
(BWI) outcomes. Evidence synthesis requires that BWI 
is reported in a consistent manner. Cochrane reviews 
investigating interventions for burns report that the 
indicators used to diagnose BWI are variable or not 
described, indicating a need to standardise reporting. 
BWI is complex and diagnosed by clinician judgement, 
informed by patient-reported symptoms, clinical signs, 
serum markers of inflammation and bacteria in the wound. 
Indicators for reporting BWI should be important for 
diagnosis, frequently observed in patients with BWI and 
assessed as part of routine healthcare. A minimum (core) 
set of indicators of BWI, reported consistently, will facilitate 
evidence synthesis and support clinical decision-making.
Aims The Infection Consensus in Burns study aims to identify a 
core indicator set for reporting the diagnosis of BWI in research 
studies.
Methods (1) Evidence review: a systematic review of 
indicators used in trials and observational studies reporting 
BWI outcomes to identify a long list of candidate indicators; (2) 
refinement of the long list into a smaller set of survey questions 
with an expert steering group; (3) a two-round Delphi survey 
with 100 multidisciplinary expert stakeholders, to achieve 
consensus on a short list of indicators; (4) a consensus meeting 
with expert stakeholders to agree on the BWI core indicator set.
Ethics and dissemination Participants will be recruited 
through professional bodies, such that ethical approval from 
the National Health Service (NHS) Health Research Authority 
(HRA) is not needed. The core indicator set will be disseminated 
through peer-reviewed publication, co-production with 
journal editors, research funders and professional bodies, and 
presentation at national conferences.
PrOsPErO registration number CRD42018096647. 
IntrOduCtIOn
Over 140 000 patients in England and Wales 
required specialised burn care between 2010 
and 2017.1 Data indicate that the majority of 
burns treated in the UK are small in size, with 
a median of between 1.0% and 2.5% of total 
body surface area affected.2 3 Patients with 
burns are susceptible to burn wound infection 
(BWI) due to the loss of the skin’s barrier to 
microbes and the impact of the burn on the 
immune system.4 It is estimated that approx-
imately 10%–20% of patients with burns will 
develop BWI before healing.4 These patients 
may experience delayed wound healing5 
and require regrafting,6 and can develop 
sepsis if left untreated. To identify the most 
effective interventions to prevent, detect and 
treat BWI, systematic synthesis of evidence 
from high-quality randomised controlled 
trials (RCTs) is needed.7
Recent systematic reviews have found that 
while RCTs typically report BWI as a single 
outcome, there is considerable variation 
in the indicators used to inform the diag-
nosis.8–10 In a Cochrane review of 36 RCTs 
evaluating the effectiveness of antibiotic 
prophylaxis in burn patients,8 15 studies did 
not describe the diagnostic indicators used, 
14 studies diagnosed burn wound infec-
tion using swab culture or biopsy with or 
without clinical signs, 4 studies used wound 
signs or clinical observation, 2 studies used 
systemic signs and one study used chondritis 
and destruction of cartilige. In another 
strengths and limitations of this study
 ► This protocol was co-produced by a multidisci-
plinary panel with expertise in diagnosing burn 
wound infection (BWI).
 ► A systematic review will be undertaken to identify all 
reported diagnostic indicators of BWI to inform the 
candidate indicator list.
 ► We will work closely with multidisciplinary stake-
holders who will be identified through professional 
bodies to participate in the Delphi survey, facilitate 
dissemination and optimise research impact.
 ► A UK focus balances limiting the application of the 
core indicator set with identifying a pragmatic, us-
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Cochrane review assessing topical therapy for facial 
burns,10 of three studies reporting BWI, three different 
indicators were used for diagnosis; one study used swab 
cultures, the second study used qualitative assessment 
of exudate and cellulitis, and the third study diagnosed 
BWI if there was chondritis. If the reporting of BWI is 
based on varying diagnostic indicators, or if the diag-
nostic indicators used are not reported, the validity of 
the findings is compromised, limiting the ability of the 
review to provide good-quality evidence to inform clin-
ical decision-making.
One explanation for this heterogeneity in the reported 
indicators used to diagnose BWI in research trials is 
that clinical diagnosis of BWI is challenging; there is no 
accepted objective method for diagnosing BWI, and diag-
nosis relies on clinical judgement. Clinical diagnosis is 
subjective4 and based on several indicators of infection. 
These include patient-reported symptoms, clinical wound 
assessment, systemic signs, the presence of bacteria in a 
wound, retrospective response to antibiotics and non-spe-
cific serum markers of inflammation. Patients typically 
need to have only some of these symptoms and signs to 
be diagnosed with, and treated for, BWI. Quantitative 
bacterial counts from swab cultures are acknowledged as 
providing only supportive information, as all wounds are 
colonised with bacteria within 48 hours of injury.11 12 Diag-
nosis is further complicated by the fact that many signs 
used in the diagnosis of BWI, such as fever and tachy-
cardia, are not specific to BWI and are present as part 
of the normal systemic inflammatory response to burn 
wound injury.13
In the absence of an objective method for diagnosing 
BWI, consensus statements have been developed with 
expert stakeholders to support diagnosis of BWI and 
sepsis. These include the American Burns Association 
(ABA14), the Centers for Disease Control and Prevention 
(CDC15) and the European Wound Management Associ-
ation (EWMA16) consensus statements. However, there 
are limitations of these statements that preclude their 
application clinically and in research. The ABA and CDC 
statements use information gathered from several poten-
tial indicators of BWI to result in a composite outcome of 
BWI. Composite outcomes of BWI have not, and cannot 
be, tested for diagnostic accuracy due to the absence of 
an objective reference standard. There are also practical 
limitations relating to the indicators used to underpin 
diagnosis. Both the ABA and CDC consensus statements 
rely on the use of wound biopsy for diagnosis of wound 
infection. Biopsies are infrequently carried out in the 
UK because they are costly, invasive, painful and require 
anaesthesia.17 The evidence base for the use of quantita-
tive microbiology, such as wound biopsies, for diagnosing 
clinically relevant BWI is limited.11 17 Limitations of the 
EWMA consensus include a lack of reference to systemic 
signs of infection and inclusion of indicators that, while 
highly sensitive, are infrequently seen in patients with 
BWI, for example, ecthyma gangrenosum. For these 
reasons, these previously developed consensus statements 
may have limited usefulness for identifying or reporting 
BWI in UK practice.
Until an evidence-based, objective reference standard 
for determining the presence of BWI is available, there is 
a need to develop a consistent approach for reporting the 
indicators used to inform diagnosis in research. Agree-
ment regarding a minimum (core) set of symptoms, signs 
and laboratory tests considered to be important in deter-
mining the presence of BWI, frequently seen in patients 
diagnosed with BWI, and assessed as part of normal care 
will allow standardisation of reporting of BWI in trials.
Aim
The Infection Consensus in Burns study (ICon-B) aims to 
achieve the development of a core indicator set to stan-
dardise the reporting of symptoms, signs and laboratory 
tests used for diagnosing BWI in research studies.
MEthOds 
Phase 1: systematic review to identify potential candidate 
indicators of bWI
A systematic review will be undertaken to identify poten-
tial indicators of BWI used in current research to evaluate 
the effects of interventions on BWI outcomes.
Identifying relevant studies
Predefined inclusion and exclusion criteria will be used 
to identify relevant studies. Included studies will be any 
peer-reviewed, published study or study protocol reporting 
an evaluation of any intervention, using a randomised or 
non-randomised trial design or an observational method-
ology. They will be included if they report the effect of an 
intervention or treatment for patients with burns, where 
a BWI outcome is reported in the study methods, results 
or discussion. Study participants will be any patient with 
a cutaneous burn injury of any cause and any size. Exclu-
sion criteria are indicated in table 1.
Search
A search string will be developed based on the above 
criteria and will comprise synonyms of burns, wound 
infection, interventions and trials or observational studies 
(see online supplementary file for example search). 
It will be applied to five databases: Ovid Medline, Ovid 
Embase, Cinahl, Cochrane Register of Clinical Trials and 
Cochrane Register of Protocols. The search will be limited 
to studies published after 1 January 2010 to ensure that 
current knowledge and practice regarding BWI are iden-
tified. Studies written in languages other than English 
will be excluded since there is no funding available for 
translation.
Selection
The inclusion and exclusion criteria will be applied by 
one researcher in two stages. These will first be applied to 
titles and abstracts identified from the search, and then 
to full texts of studies retained following title and abstract 
screening. At each stage. a second researcher will review 
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20% of the screened studies for inclusion, and reasons for 
exclusion, to ensure reliability of study selection.
Data extraction
A pro forma will be developed to conduct systematic data 
extraction with fields relating to study design, interven-
tion/s tested, participant age, gender, burn size and mech-
anism of injury. Verbatim reports of each indicator for the 
diagnosis of BWI will be extracted and, where provided, 
the methods for assessing the indicator (eg, bacterial 
samples taken using swab) and any standard parameters 
used to determine the presence of infection (eg, body 
temperature >38°C, bacterial count of 105 microbes 
per gram of tissue). One reviewer will conduct all data 
extraction with a second reviewer extracting data from 
20% of studies, to ensure reliability of data extraction. 
Disagreements will be discussed, and a third reviewer will 
facilitate decision-making where required. Second-re-
viewer checking of data extraction will be continued until 
consistency is achieved.
Data analysis and reporting
The extracted indicators will be tabulated and exam-
ined. Similar indicators will be grouped. A second 
reviewer will review groupings, and disagreements will be 
resolved through discussion. Where previously described 
tools (eg, ABA, CDC and EWMA consensus statements) 
have been used to diagnose presence of infection, this 
will be reported. Their incorporated indicators will be 
deconstructed for inclusion in the long list of candidate 
indicators.
Phase 2: reduction of the long list of indicators into a shorter 
list
The long list of BWI indicators identified in the described 
systematic review will be reduced by removing duplicates. 
A steering group will be convened comprising clinicians 
(doctors, nurses and microbiologists) and researchers 
with an interest in burns. A face-to-face steering group 
meeting will be held to review the long list of indicators. 
Each single indicator or grouping will be assigned a label. 
The labels will be refined through discussion to achieve 
a clear definition for each. The labels will be categorised 
into patient-reported symptoms, clinically observed signs 
or laboratory tests.
Phase 3: achieving consensus about bWI indicators using an 
online delphi survey
A modified Delphi method will be used, comprising two 
questionnaire rounds and a final consensus meeting.
An online questionnaire will be developed using 
REDCap18 to enable distribution of the questionnaire to a 
wide stakeholder audience. Before use, the questionnaire 
will be piloted with a small number of stakeholders from 
all relevant groups to check understanding and ease of 
use, as well as data capture and feedback processes.
sample
There is no agreed standard sample size for conducting a 
Delphi survey.19 Up to 100 stakeholders representing the 
different staff involved in BWI diagnosis will be recruited, 
including consultant surgeons working in burn care, 
junior medical and nursing staff with at least 3 months' 
experience of burn care, clinical microbiologists working 
in burn services, and general practitioners and emer-
gency department staff who report that they see at least 
one patient with suspected BWI per month. Stakeholders 
will be recruited through mass email to the memberships 
of appropriate professional groups (eg, the British Burns 
Association, Care of Burns in Scotland, Royal College 
of General Practitioners/Emergency Medicine, Associa-
tion for Clinical Biochemistry and Laboratory Medicine, 
Healthcare Infection Society and British Society of Anti-
microbial Chemotherapy). We will aim to ensure an even 
distribution of respondents between groups.
Questionnaire round 1
Participants completing the survey will be asked to rate 
each of the BWI indicator items on three scales:
1. The importance of the indicator for reporting pres-
ence of BWI in research, for example, ‘How important 
is this indicator in diagnosing BWI?’
Participants will indicate their responses to each indi-
cator on a 9-point Likert-type scale ranging from 1 to 9 
with written anchors to indicate 1–3 (not at all impor-
tant), 4–6 (important but not essential) and 7–9 (very 
important). Participants may indicate that they have 
no view about the indicator where appropriate.
2. The frequency with which the indicator is seen in 
patients with BWI, for example, ‘How frequently do 
Table 1 Inclusion and exclusion criteria for systematic review
Inclusion criteria Exclusion criteria
 ► Trial or observational study assessing the impact of an 
intervention for patients with burns.
 ► Reports a burn wound infection outcome in the methods, 
results or discussion.
 ► Not written in English.
 ► Not exclusively about burns (eg, trauma population).
 ► Non-human subjects.
 ► Laboratory based, not carried out in clinical setting (eg, 
exudate or blood samples from humans tested within 
laboratory).
 ► Does not report a burn wound infectionoutcome.
 ► Abstract, systematic review or commentary paper.
 ► Not a trial or observational study reporting an intervention 
to treat burn injuries.
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you see this symptom/sign in patients diagnosed with 
BWI?’
Participants will respond to each indicator on a 9-point 
Likert-type scale ranging from 1 to 9, with written an-
chors to indicate 1–3 (never seen), 4–6 (sometimes 
seen) and 7–9 (seen in most patients diagnosed with 
BWI). Participants may indicate that they have no view 
about the indicator where appropriate.
3. Whether the indicator is or can be assessed as part of 
normal practice for a patient with burns, for exam-
ple, ‘Do you regularly use this indicator to establish 
the presence or absence of BWI in your day to day 
practice?’
Participants will respond by indicating whether they 
would normally assess the indicator as a Yes or No. 
Participants may indicate that they have no view about 
the indicator where appropriate.
At the end of the survey, participants will be invited 
to state any further indicators not included that they 
believe are important for consideration in the second 
survey round.
Calculating consensus about items
The distribution of ratings for each indicator relating to 
(1) importance and (2) frequency with which the indi-
cator is seen in patients with BWI will be graphed and 
examined. Percentages will be calculated for the number 
of participants rating the item 1–3 (not at all important/
never seen), 4–6 (important but not essential/sometimes 
seen) and 7–9 (very important/seen in most patients 
diagnosed with a wound infection). Additionally, the 
percentage will be calculated of participants indicating 
that they (3) assess the indicator as part of normal prac-
tice (% stating yes/no).
Indicators carried through to the second round of the Delphi
Indicators will only be carried through to the second 
round of the Delphi where ≥75% of the sample indi-
cate that they assess it as part of normal practice. If this 
criterion is met, indicators will then be assessed as to 
whether there is consensus that the item is important 
and/or frequently seen. Definitions of consensus vary 
between Delphi surveys; it is accepted that there is a need 
to balance being so inclusive that a parsimonious core 
indicator set is not achieved, with using such stringent 
criteria that important indicators are missed.20 In several 
recent core outcome set protocols and studies using 
Delphi methodology, a threshold of 70% of the sample 
agreeing that a criterion is important has been used.21–23 
In the current study, a more stringent threshold of ≥75% 
of the sample falling within the bottom1–3 or top third of 
the scale7–9 of the importance and frequency scales will 
indicate consensus about the importance/frequency with 
which an indicator is seen, only where a maximum of 
15% of the sample rates it in the opposing third.
Therefore, indicators to be carried forward to the 
second round of the survey are those where ≥75% of 
the sample rates it as 7–9 on the Likert-type scale, with 
≤15% of the sample rating it as 1–3. Indicators will also 
be carried through to the second round where there is 
no consensus about their importance or frequency; that is, 
fewer than ≥75% of the sample rates it in either the top or 
bottom third of the scale.
Items will be removed from the indicator list and not carried 
through to the second round if
1. ≤74% report that they do not assess it as part of their 
normal practice.
2. There is consensus that the indicator is unimportant 
OR infrequently seen in patients with BWI, whereby 
>75% of the sample rates it as 1–3, and ≤15% rates it as 
7–9 on these scales.
round 2
Participants completing the first questionnaire will receive 
a second survey, comprising the indicators retained from 
the previous round, using the same item and response 
format. Additional indicators provided by the respon-
dents in the first round will be incorporated into the 
second survey round.
In addition, participants will receive tailored feedback 
showing their own and other stakeholders’ responses 
to each indicator, including the central tendency (eg, 
mean, median or mode) and distribution of ratings for 
each item (eg, SD or IQR). Methods for establishing the 
most effective means for presenting this information will 
be piloted prior to survey development. It is not antic-
ipated that feedback will be provided indicating item 
scores according to stakeholder group. However, if there 
is disparity in responses between groups of stakeholders, 
this decision will be considered by the study steering 
group.
Participants will be invited to revisit and, if desired, 
alter their rating for each item and to restate their ratings 
for each indicator in relation to (1) importance, (2) 
frequency and (3) whether it is used for diagnosis.
Indicators carried through to the stakeholder meeting
Indicators will be taken to the stakeholder meeting if 
they meet the proceed criteria described above. More 
stringent criteria may be applied if it is apparent that this 
process has not reduced the potential indicator list to an 
acceptable number.
Phase 4: stakeholder consensus meeting
All survey participants will be invited to a consensus 
meeting. During this meeting, data will be presented 
regarding counts/frequency, or central tendency, and the 
distribution of scores for each indicator relating to (1) 
whether it is assessed, (2) importance and (3) frequency 
with which it is observed in patients considered to have 
BWI. Following review of all indicators, participants will 
be invited to prioritise indicators for inclusion using 
anonymous electronic voting software. A final list of indi-
cators will be agreed and a method for reporting the core 
indicator set in research will be discussed.
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Public and patient involvement
Patients and members of the public were not involved in 
the development of this protocol, since diagnosis of BWI 
is made by clinicians.
Ethics and dissemination
Recruitment of stakeholder participants will take place 
outside of National Health Service (NHS) organisations 
and through professional bodies. Therefore, Health 
Research Authority and research ethics approvals are not 
required to conduct the survey. 
The findings of the systematic review will be presented at 
relevant burns research-related  and wounds research-re-
lated conferences and will be written up for publication. 
The findings of the review will directly inform the items 
used in the Delphi survey and stakeholder consensus 
event. Following establishment of a set of core reporting 
criteria, we will disseminate the findings as a peer-re-
viewed journal article, and through appropriate profes-
sional conferences. We will work with journal editors 
from relevant journals and will disseminate our findings 
to relevant funders to increase awareness of the core 
reporting criteria. 
dIsCussIOn
Heterogeneous methods and reporting limits the extent 
to which evidence synthesis using data from RCTs can 
provide valid information about the effectiveness of treat-
ments. Systematic literature reviews of treatments for 
patients with burns demonstrate that there is variation in 
the indicators used to diagnose BWI in trials, limiting the 
conclusions that can be drawn about the effectiveness of 
treatments. In the absence of an objective means of diag-
nosing BWI, agreement about a set of the most important 
(core) symptoms, signs and laboratory tests (indicators) 
for diagnosing BWI will standardise research reporting. 
This will result in evidence syntheses that provide more 
valid information about treatment effects. This protocol 
describes a systematic and pragmatic multiphase approach 
to developing a core indicator set for BWI, taking account 
of expert views from the multidisciplinary team involved 
in BWI diagnosis.
The Delphi methodology is one method to develop 
consensus among experts on a given topic. It has been used 
previously to establish consensus between experts about 
core outcomes to be assessed in various healthcare domains 
and has been found to improve consistency of outcome 
reporting between studies.24 This methodology has also 
been used to agree key diagnostic criteria for clinical condi-
tions for which there is no objective diagnostic method, 
including for bone and joint infections in children25 and 
hepatic and renal cyst infection.26 It is important to note 
that the proposed methodology for developing the core 
indicator set is not intended to identify those indicators that 
are most predictive of BWI diagnosis. Rather, its purpose is 
to identify which indicators multidisciplinary stakeholders 
agree are important and applicable to routine patient care 
in the UK, to standardise the reporting of BWI in research 
studies. It should also be noted that while the resulting list 
of indicators is a recommended minimum that should be 
reported, it will not preclude the reporting of data relating 
to other indicators relevant to BWI diagnosis, should 
researchers wish to do so.
The proposed work addresses the practical limitations 
of previously developed consensus-based criteria for diag-
nosing BWI (ABA,27 CDC15 and EWMA28). These consensus 
statements provide a limited basis for a core indicator set 
since they include tests that are not currently widely used 
in NHS practice (eg, wound biopsy, ABA and CDC), and 
prioritise signs of BWI that are infrequently seen in patients 
with burns (eg, ecthyma gangrenosum, EWMA28). Our 
proposed study aims not only to take account of whether the 
indicator is viewed as important in the diagnosis of BWI, but 
also to ensure that the indicator is likely to be seen and can 
be assessed in patients with burns. This will ensure that the 
resulting core indicator set is applicable and relevant to care 
in the UK, and that data about the indicators can be readily 
captured for reporting in research studies.
A limitation of the current work is that the literature 
search to identify current indicators used to diagnose BWI is 
limited to studies published in English, and that the Delphi 
survey will only be conducted in the UK. Nonetheless, a 
global perspective is brought through the identification of 
international studies published in English. The practical 
applicability of the core indicator set to NHS practice is 
balanced against the potential that other indicators than 
those identified by a UK stakeholder group may be consid-
ered of equal or greater importance and usefulness by an 
international audience.
Impact and dissemination
To ensure effective uptake of the core indicator set by burn 
care researchers, early buy-in is essential. By engaging and 
working closely with the multidisciplinary stakeholder 
steering group to develop the questions for the Delphi 
study, and the active participation in the Delphi survey by 
a wide group of relevant clinical stakeholders, we hope 
to ensure future uptake of the resulting core indicator 
set by its intended audience. We aim to publish the core 
indicator set in a burns-specific journal to reach poten-
tial users. Further, we will engage with editors of appro-
priate journals and the Cochrane Collaboration Wounds 
Group to facilitate its take-up for trial reporting. Dissem-
ination of the core indicator set and the development 
work underpinning it described here will be carried out 
through presentations at appropriate wound-related and 
burn-related conferences.
COnClusIOn
The ICon-B study aims to identify a core set of indicators 
to standardise the reporting of BWI in research studies. 
The indicators will be those considered to be important 
for identifying the presence of burn wound infection, 
frequently observed in patients with BWI and assessed as 
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part of usual care. A systematic approach to identifying 
candidate signs, symptoms and tests will be undertaken. 
The participation of end-user stakeholders to reach 
consensus about their inclusion will optimise buy-in and 
impact for the final core indicator set. This will result in 
consistent recording of data about burn wound infec-
tion across studies and will allow the accumulation and 
comparison of evidence to identify the most effective 
treatments for patients with burns in relation to BWI.
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